Ateptidase
PreclinicalProtein / enzyme
Ateptidase is one of 14 small molecule programs targeting Intracranial Hemorrhage. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Intracranial Hemorrhage
#DrugCompanyPhaseTrials
1Savaysa
Daiichi SankyoApproved
Colcrys
Alnylam PharmaceuticalsApproved
Atorvastatin Calcium
Merck & Co.Approved
Eliquis
Bristol-Myers SquibbPhase 3
Luminal
BBiomed Industries, Inc.
Phase 3
Anticoagulants
SanofiPhase 3
Immunoglobulin Therapy
RochePhase 2
Recombinant Interferon Alfa 2a
RochePhase 1
Prothrombin Complex Concentrate
CSL BehringPhase 1
Fresh Frozen Plasma
CSL BehringPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Intracranial Hemorrhage1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ateptidase. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Preclinical[1]
- Company
- ZZhujiang Hospital